Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special drug use surveillance for Entresto in chronic heart failure (CLCZ696B1401)
jRCT2031200432Completed
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in chronic heart failure (CHF), sponsored by Novartis. Primary endpoint: Safety of Entresto in chronic heart failure patients. Started Mar 2021; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCT2031200432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200432.